AVTX
AVALO THERAPEUTICS INC
Latest close $19.09 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Initial Schedule 13G | Initial Schedule 13G | 3.4M | 12.00% | $18.48 | $19.50 | $19.09 |
| Fidelity / FMR CIK0000315066 | May 29, 2026 observed Jun 5, 2026 filed · 7d Schedule 13G amendment | Earliest Schedule 13G amendment found | 3.2M | 12.00% | $15.95 | $13.10 | $19.09 |
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed May 15, 2026 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 2.2M | 12.00% | $14.93 | $17.74 | $19.09 |